Drug Trial Radar · NCT02960594
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Dec 2014
Primary completion
Nov 9, 2018
Study completion Nov 9, 2018
Sponsor
- Lead sponsor
- Inovio PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- University of Pennsylvania; University of North Carolina; Thomas Jefferson University; University of Pittsburgh; Barbara Ann Karmanos Cancer Institute; Mayo Clinic
- First posted
- Nov 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.
Conditions
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Head and Neck Cancer
- Ovarian Cancer
- ColoRectal Cancer
- Gastric Cancer
- Esophageal Cancer
- HepatoCellular Carcinoma
Interventions
INO-1400Biological
INO-9012Biological
INO-1401Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03Time frame: Up to 2 years from first study treatment
- Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration siteTime frame: Up to 14 weeks
- Changes in safety laboratory parametersTime frame: Up to 2 years from first study treatment
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
University of North Carolina
Chapel Hill, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.